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Abstract
Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders in 
women of reproductive age. The clinical picture characterized by both endocrine disor-
ders (hyperandrogenism, menstrual cycle disorders, obesity) and metabolic alteration 
with implications for women’s health and reproductive and metabolic consequences. 
Leventhal described for the first time a syndrome characterized by polycystic ovaries 
associated with menstrual cycle disorders, hirsutism, and obesity. The pathophysiol-
ogy and other metabolic disorders that make the PCOS more complex than originally 
described are the most common cause of infertility linked to chronic anovulation. In fact, 
this is a multifactorial disorder that involves the hypothalamus, pituitary, ovary, adrenal, 
and peripheral adipose tissues, which are simultaneously involved in the pathogenesis 
of the syndrome.
Keywords: infertility, polycystic ovary (PCO), polycystic ovarian syndrome (PCOS), 
menstrual irregularities, acne, hirsutism, anovulation, obesity, hyperandrogenism, 
insulin resistance and hyperinsulinemia, metformin
1. Introduction
Polycystic ovary syndrome (PCOS) is a common endocrine disorder among women of repro-
ductiveage. It was described for the first time by Stein and Leventhal in 1935 [1].
The PCOS Consensus Workshop Group has proposed a review of diagnostic criteria, defining 
PCOS as the presence of at least two of the following criteria together [2]:
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the t rms of the Crea ive
Comm ns Attribution Lic nse (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
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• Oligo-anovulation
• Hyperandrogenism with clinical or biochemical signs
• Polycystic ovary appearance on ultrasound examination
In order to establish the diagnosis of PCOS, it is important to exclude other disorders with 
a similar clinical presentation, such as congenital adrenal hyperplasia, Cushing’s syndrome, 
and androgen-secreting tumors.
2. Clinical presentation and clinical components in polycystic ovary 
syndrome (PCOS)
2.1. Menstrual irregularities in women with polycystic ovary syndrome (PCOS)
This often occurs during the adolescent period at the menarche with menstrual irregulari-
ties mainly oligomenorrhea or less frequently amenorrhea. Over 70% of women with PCOS 
spontaneously reach menstrual regularity in the fourth decade of their life with metabolic 
dysfunction mainly in perimenopausal age [3]. The chronic state of anovulation present in 
these patients will produce amenorrhea and oligomenorrhea. An elevated pulse frequency 
for the luteinizing hormone (LH) has been documented [4]. The increased pulse frequency of 
the hypothalamic gonadotropin-releasing hormone (GnRH) promotes the transcription of the 
LH beta-subunit compared to the follicle-stimulating hormone (FSH) beta-subunit [5]. It is 
unclear whether this increase in pulse frequency is due to an inherent anomaly of the GnRH 
pulse generator or caused by low progesterone levels due to the chronic state of anovulation 
as progesterone slows down the GnRH pulse generator [6].
Most women with this syndrome exhibit oligomenorrhea with irregular vaginal bleeding epi-
sodes. The cause of such bleeding is not always referred to ovulation but may be caused by a 
sudden drop in plasma estrogen levels [7].
Increased ovarian androgen biosynthesis in the polycystic ovary syndrome results from abnor-
malities at all levels of the hypothalamic-pituitary-ovarian axis [8]. The etiopathogenesis of PCOs 
is multifactorial; all these factors act by creating a vicious circle that eventually leads to the syn-
drome. It is not yet clear at present what pathogenic event that triggers the chain reaction that 
leads to hyperandrogenism. The clinical manifestation of PCOs is the result of a series of altera-
tions of physiological mechanisms, so there is not always a full expression of this syndrome. 
PCOs usually occur in puberty with menstrual disorders, hirsutism, and obesity. Alongside 
endocrine disorders, there are also metabolic disorders which, however, become more and 
more evident with the progress of time until they become predominant after menopause.
3. Obesity
Obesity is present in 30–60% of patients with PCOS with body mass index (BMI) greater than 
30 kg/m2 and is often associated with a state of hyperinsulinism. However, even in this case, 
Pathophysiology - Altered Physiological States204
the cutoff choice can be discussed and modified on the basis of geographical and socioeco-
nomic considerations. The presence of obesity in women with PCOS results in worsening in 
the metabolic and reproductive outcomes [9].
Obese women with PCOS compared to women with normal weight with PCOS have increased 
prevalence of glucose intolerance and type 2 diabetes mellitus [10], higher prevalence of hir-
sutism [11], greater risk of metabolic syndrome, and therefore cardiovascular disease [12, 13]. 
Obesity increases the prevalence of obstructive sleep apnea in patients with PCOS [14].
A lipolysis dysregulation in PCOS patients has been documented [15], as an increased lipoly-
sis of visceral fat resulting in an increase in free fatty acids released directly into the portal 
circulation. The free fatty acid levels in the hepatic portal circulation are the major modulators 
of hepatic gluconeogenesis [16]. This increased visceral fat lipolysis may be one of the mecha-
nisms for increased risk of glucose intolerance [17].
In obese women with PCOS, physical activity and low-calorie diet intake lead to an improve-
ment in ovarian function and reduction of the risk of type 2 diabetes mellitus [18]. Exercise and 
weight control are highly recommended because of their direct effect not only on the metabolic 
framework but also on ovarian function and restoration of fertility [19]. Success in treating obesity 
requires a multidisciplinary approach involving the dietician, the psychologist, and the physician.
4. Hirsutism
The perception of hirsutism as a problem depends on cultural and ethnic factors. The com-
monly used Ferriman-Gallwey score for clinical evaluation and score above 8 is considered 
diagnostic [20]. The fact remains that it is an extremely subjective assessment.
The incidence of hirsutism in Caucasian women is 60–70%, while in Japanese women is 
30% [21].
In PCOS patients, hyperinsulinism also contributes to increased adrenal androgen secretion 
in part by increasing adrenal sensitivity to adrenocorticotropic hormone (ACTH) action [22].
4.1. Acne
It is a polymorphic dermatitis sustained by a chronic inflammatory process of the hair follicle. 
In the genesis of acne, four pathological events are distinguished: follicular channel hyper-
keratosis, sebaceous hypersecretion, bacterial proliferation, and inflammation.
Chronic hyperandrogenism causes an increase in sebaceous secretion, thus forming a cystic 
collection resulting in bacterial overlap and thereby stimulating the inflammatory process. It 
has been estimated roughly that one-third of PCOS patients have acne [23, 24].
4.2. Infertility
The main cause of infertility in PCOS women is chronic anovulation. However, subfertility 
may be related to the increase of plasma LH levels in the follicular phase of the cycle, caus-
ing a resumption of the second meiotic division of the oocyte and the release of premature 
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ovocytes [25]. High levels of luteinizing hormone (LH) found in polycystic ovary syndrome 
seem to be related to increased frequency of spontaneous abortions. Other factors that connect 
PCOS and spontaneous abortion are not yet well known; however, various factors involved 
in steroidogenesis, folliculogenesis, oocyte maturation, and reduced endometrial receptivity 
contribute to this vicious cycle between PCOS and abortion [26].
4.3. Insulin resistance and hyperandrogenism in PCOS
There are numerous evidence that polycystic ovary syndrome (PCOS) is a disorder character-
ized by insulin resistance and hyperinsulinemia.
Insulin resistance is a condition for which a normal insulin concentration produces attenuated 
biological effects in cases where pancreatic function is intact, leading to compensatory hyper-
insulinemia. The presence of insulin resistance does not imply systematic glucose intolerance, 
and blood glucose may be normal.
Prospective and retrospective observational studies show that at least 40% of women with 
PCOS exhibit glucose intolerance and that in the 10–20% will develop type 2 diabetes mellitus 
later in their life between the age of 55 and 65 years [27, 28].
Prior to the development of glucose intolerance, the defect of insulin secretion may remain 
latent and only occur in conditions that increase insulin resistance, such as the onset of gesta-
tional diabetes or a glucose intolerance in the case of corticosteroid treatment.
The molecular mechanism responsible for insulin resistance in PCOS appears to be unique 
and specific for this syndrome and different from the one present in obesity. Altered phos-
phorylation of the insulin receptor has been described, resulting in a lack of signal transduc-
tion [29].
The ovarian tissue in women with PCOS remains sensitive to the action of insulin, although 
there is a systemic resistance to insulin.
Ovarian stimulation seems to involve a signal transduction system other than glucose trans-
port, in particular a different second messenger, probably inositol phosphoglycan [30, 31].
Insulin and insulin-like growth factor 1 (IGF-1) are important regulators of ovarian function 
and directly and indirectly affect ovarian steroidogenesis and androgenic status. Insulin acts 
directly on the ovarian cells of the theca by activating cytochrome P450 c17alpha hydroxylase 
and 17,20-lyase activity (key enzyme in the synthesis of androgens) and also synergistically 
promotes the synthesis of androgen induced by the LH.
Insulin acts indirectly by suppressing the circulating levels of sex hormone-binding globulin 
(SHBG), resulting in increased free testosterone, and the fraction of the bioavailable hormone 
for tissues.
Finally, insulin may suppress liver synthesis of IGF-1-binding protein (IGFBP-1), thereby 
increasing the bioavailability of IGF-1, another important regulator of androgenic ovarian 
synthesis. It also appears that insulin may act at the hypothalamus level by modifying the 
pulsed secretion of LH, thus also affecting ovarian steroidogenesis (Figure 1) [32, 33].
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There is currently no insulin resistance screening test, whereas a criterion for defining met-
abolic syndrome has been established that includes components associated with insulin 
resistance syndrome including visceral obesity, hypertension, fasting hyperglycemia, and 
dyslipidemia [34]. Other groups add the oral glucose tolerance test (OGTT) to evaluate the 
fasting blood glucose and at a distance of 2 hours after an oral dose of 75 g of glucose [34].
These characteristics make women with PCOS at increased risk of metabolic syndrome, defined 
in the past as X syndrome or insulin resistance syndrome [35]. Metabolic abnormalities in women 
with PCOS therefore require a change in the clinical approach to this syndrome, recognizing 
that this condition is chronic and with possible long-term consequences. The metabolic disor-
ders linked to insulin resistance usually become predominant with age advancement (Figure 2).
The most common metabolic disorders are those that are traditionally linked to insulin resis-
tance and usually become predominant with age advancement.
4.4. Role and issues of ultrasound in the diagnosis of PCOS
Initially, Adams’s ultrasound criteria have been used for ultrasound assessment of the ovaries 
in women with PCOS which required 10 or more  follicles with a diameter of 2–10 mm around 
an  hyperechogenic stroma [37, 38]. Although they are still the most widely used, Adams’ cri-
teria are not universally accepted for the diagnosis of polycystic ovary basically because there 
is a considerable overlap between the normal ultrasound aspect and that of polycystic ovaries 
regarding the number of follicles and the size of the ovaries, and therefore no reliable cutoff 
has been identified with satisfactory sensitivity and specificity.
Transvaginal ultrasound is the most commonly used for diagnosis of polycystic ovary (PCO). 
Ultrasound criteria were subsequently modified resulting in increased ovarian volume 
(>10 cm3) and the presence of >12 follicles in diameter of 2–9 mm in at least one ovary for 
PCOS diagnosis [39].
Figure 1. Factors involved in  altering follicular steroidogenesis.
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Women who use oral contraceptives should be excluded from this criterion as they mod-
ify ovarian morphology in healthy women and probably even in women with polycystic 
ovary [2].
The prevalence of polycystic ovary depending on the age of women: 21.6% in women 
<35 years and 7.9% in women >35 years [40].
The ultrasound aspect of polycystic ovary can be an isolated finding in asymptomatic patients 
as well as patients with typical clinical and biochemical manifestations of PCOS may have 
morphologically normal ovaries.
The variability of the ultrasound description of ovarian morphology (number and location of 
follicles, hyperechogenic stroma) is a fact even though recent studies consider the increase in 
ovarian volume (>10 cm3) as the most reliable criterion for ultrasound evaluation of PCOS [41].
The characteristic ultrasound feature is an increase in  ovarian stroma vascularization at 
Doppler ultrasound [42, 43], which in turn may be related to changes in ovarian morphol-
ogy. It is necessary to clarify the correlation between ovarian volume and stromal vascu-
larization with ovarian steroidogenesis in patients with PCOS. It is believed that vascular 
endothelial growth factor (VEGF) plays an important role in increasing stromal flow in 
patients with PCOS (Figure 3) [44].
4.5. Combined oral contraceptive pills in PCOS patient
Combined oral contraceptives (COC) are the most widely used therapeutic option for treating 
menstrual irregularities. Oral contraceptives cause suppression of LH, resulting in a reduc-
tion in androgenic ovarian secretion. The estrogenic component of the combined oral contra-
ceptive induces an increase in sex hormone-binding globulin (SHBG) hepatic synthesis. The 
various progestogen components of the COC have different effects on the circulating levels of 
the SHBG [45]. Combined oral contraceptives also significantly reduce the risk of endometrial 
cancer [45].
The COC pills containing ethinylestradiol and a progestogen with antiandrogenic activity 
(cyproterone acetate or drospirenone) are effective for the treatment of hirsutism in women 
Figure 2. Criteria for metabolic syndrome [36].
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with PCOS. The duration of this treatment for at least 6 months is related to the long physi-
ological duration of the hair follicle, while the effect on acne is faster [46].
The best combined oral contraceptive for patients with PCOS is still not well identified. 
Recent studies have shown that COC therapy may at least partly cause a further worsening 
of insulin sensitivity in PCOS patients despite a significant reduction in circulating andro-
gens [47, 48].
The effect of COC on insulin balance in women with PCOS remains uncertain. Although the 
use of combined oral contraceptives is not associated with increased risk of type 2 diabetes 
mellitus in the general population, studies in women with PCOS have shown mixed results, 
and this risk cannot be excluded [49].
4.6. Insulin-sensitizing drugs as new therapeutic approach in PCOS
In recent years, numerous studies have been conducted on the use of insulin-sensitizing drugs 
such as metformin in women with PCOS.
Considering the evidence that insulin resistance and hyperinsulinemia would play a patho-
genic role in the development of polycystic ovary syndrome. Metformin improves insulin 
resistance by reducing glucose intestinal absorption and gluconeogenesis. It also increases the 
circulating levels of SHBG and FSH with improved ovarian steroidogenesis and normalization 
of follicular growth [50].
A systematic review evaluated the effectiveness of insulin-sensitizing drugs in women 
with PCOS. Metformin administration in women with PCOS is associated with a reduction 
in serum insulin levels and free and total testosterone levels [51]. In short-term therapies 
(3–6 months), it promotes spontaneous ovulation [51]. There is a decrease in blood pressure 
Figure 3. Ultrasound assessment of the polycystic ovary: international consensus definition [39].
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and LDL cholesterol, whereas the effect on body mass index is not significant [51]. Insulin-
sensitizing drugs seem to improve some of the clinical parameters of PCOS, but there is not 
enough evidence of their safety and efficacy in long-term therapies [51].
4.7. Endometrial hyperplasia and the risk of endometrial cancer in PCOS patient
The presence of chronic anovulation leads to an increase of estrogen levels which, over the 
years, can lead to endometrial hyperplasia and increased risk for endometrial cancer [52].
In women with PCOS, there may be obesity and type 2 diabetes mellitus, two conditions asso-
ciated with increased risk for endometrial cancer.
Women suffering from  PCOS and severe oligomenorrhea (interval of more than 3 months 
between menstruations) or amenorrhea, a cyclic treatment for 12 days with a progestogen to 
induce bleeding every 1–3 months [53]. It also recommended a hysteroscopy and endometrial 
biopsy in the case of ultrasound thickening of the endometrium [53].
5. Conclusions
The natural history of the polycystic ovarian syndrome and the role of possible extra-ovarian 
factors such as obesity, insulin resistance, and environmental factors in the manifestations of 
the phenotype of PCOS are the subject of scientific debate.
The sonographic finding of polycystic ovary (PCO) appearance, even if isolated, needs more 
attention in its clinical evaluation.
Polycystic ovary (PCO) pathogenetic evolution toward a PCOS phenotype is not yet well 
codified. The pathogenesis of PCOS and its natural history are the determining factors for 
a real assessment of PCOS. However, longitudinal studies are needed to better clarify the 
pathophysiology of PCOS and its impact on reproductive health.
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